Compare YARW & GGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YARW | GGZ |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.6M | 129.0M |
| IPO Year | 2017 | 2013 |
| Metric | YARW | GGZ |
|---|---|---|
| Price | $30.47 | $15.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 109.1K | 4.5K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.00 | $13.35 |
| 52 Week High | $44.28 | $17.08 |
| Indicator | YARW | GGZ |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 35.40 |
| Support Level | N/A | $15.33 |
| Resistance Level | $33.73 | $16.51 |
| Average True Range (ATR) | 3.46 | 0.23 |
| MACD | -0.08 | -0.09 |
| Stochastic Oscillator | 41.27 | 13.96 |
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.